About Dragonfly Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to ...

Dragonfly has a deep pipeline of wholly-owned TriNKETs™ discovered using its TriNKET Platform that are progressing towards the clinic, as well as productive collaborations with Celgene and Merck.

AbbVie successfully licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019, in January 2021. Jonathon Sedgwick, Vice President ...

In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly's phase 1/2 study of DF1001, an immune engaging TriNKET® targeting HER2 ...

Dragonfly’s pipeline consists of six preclinical candidates: a solid tumor targeting candidate, DF1001, four blood tumor targeting candidates (DF2001, DF3001, DF4001, and DF5001), and a TriNKET ...

Merck & Co. plans to develop new solid tumor cancer immunotherapies using Dragonfly Therapeutics’ Tri-specific NK cell Engagement Therapies (TriNKET™) technology platform, through a ...

Dragonfly Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness ...

Gilead Sciences announced an agreement Monday morning with Dragonfly Therapeutics to pay $300 million for its 5T4-targeting natural killer (NK) cell investigational immunotherapy program, DF7001. The ...

Cambridge, Massachusetts-based Dragonfly has signed an R&D collaboration the U.S. Big Pharma across a series of solid tumor targets using its so-called TriNKET platform, which generates bridges ...

Merck executes option to license its first immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets. WALTHAM, Mass., Dec. 1, 2020 /PRNewswire/ -- Dragonfly ...

In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly's phase 1/2 study of DF1001, an immune engaging TriNKET® targeting HER2 ...